Skip to main content
GUANGDONG VTR BIO-TECH CO., LTD. logo

GUANGDONG VTR BIO-TECH CO., LTD. — Investor Relations & Filings

Ticker · 300381 ISIN · CNE100001RJ8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,043 across all filing types
Latest filing 2026-05-15 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300381

About GUANGDONG VTR BIO-TECH CO., LTD.

https://www.yiduoli.com

GUANGDONG VTR BIO-TECH CO., LTD. specializes in the research, development, and manufacturing of biological enzyme preparations and steroid hormone products. The company’s portfolio includes a wide range of feed enzymes, food enzymes, and textile enzymes, as well as functional feed additives and pharmaceutical intermediates. Its operations focus on providing high-performance biological solutions for animal nutrition, food processing, and pharmaceutical manufacturing. Utilizing advanced fermentation and purification technologies, the company produces key products such as phytase, xylanase, and various steroid hormone APIs. The organization prioritizes technical innovation to improve production efficiency and support sustainable industrial practices. Its products are distributed to a global market, catering to diverse technical requirements in biological and chemical applications.

Recent filings

Filing Released Lang Actions
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an official announcement detailing the resolutions passed at the company’s 2025 Annual General Meeting, including vote counts (for/against/abstain) on each agenda item. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA), as it reports the outcomes of shareholder votes at the AGM.
2026-05-15 Chinese
北京德恒（深圳）律师事务所关于溢多利2025年年度股东会的法律意见
Regulatory Filings Classification · 85% confidence The document is a legal opinion letter issued by an external law firm regarding the convening, procedures, attendee qualifications, voting process, and outcomes of the company’s 2025 Annual General Meeting. It does not itself constitute AGM materials (presentations), an annual report, or any of the specific financial filings (10-K, IR, ER, etc.), nor is it a proxy solicitation or notice of dividend. Rather, it is a compliance/legal attestation. Under the classification guidelines, such external legal opinions and officer certifications are categorized as general regulatory filings (RNS).
2026-05-15 Chinese
关于回购股份注销完成暨股份变动的公告
Transaction in Own Shares Classification · 85% confidence The document is a formal announcement by Guangdong Yiduoli Biotech Co., Ltd. regarding the completion of its share repurchase program, the cancellation of 10,887,600 repurchased shares, and the resulting reduction in registered capital and change in share capital structure. It details the repurchase implementation, cancellation date, regulatory compliance, and updated share figures. This aligns with the definition of a Transaction in Own Shares (POS), which covers share repurchase and cancellation disclosures.
2026-05-13 Chinese
关于作废2025年限制性股票激励计划部分已授予尚未归属的限制性股票的公告
Regulatory Filings Classification · 85% confidence The document is an official corporate announcement by Guangdong Wendoleri Biotech regarding the cancellation of part of its 2025 restricted stock incentive plan. It does not present full financial results (so not an Annual Report, Interim Report or Earnings Release), nor is it a transcript, voting results, delisting notice, dividend notice, or management change. It specifically addresses adjustments to an equity incentive plan, which falls outside the other narrowly defined categories (e.g., share issues, buybacks, proxy materials). Accordingly, it is best classified as a general regulatory announcement under the fallback category "Regulatory Filings (RNS)."
2026-04-24 Chinese
第八届董事会第十八次会议决议公告
Regulatory Filings Classification · 21% confidence The document is an announcement of the board of directors’ meeting resolutions (“第八届董事会第十八次会议决议公告”), listing vote outcomes on various proposals (annual report, profit distribution, remuneration, audit appointments, fund usage, etc.). It is not the full annual or interim report itself, nor an earnings release, nor a proxy statement, nor a voting results announcement at a shareholder meeting. It also does not announce changes in board composition. There is no specific fitting category for “board resolutions” other than the general fallback “Regulatory Filings”. Therefore it should be classified as an RNS.
2026-04-24 Chinese
非经营性资金占用及其他关联资金往来的专项说明
Audit Report / Information Classification · 85% confidence The document is a standalone special-purpose explanation of the company’s non-operating fund occupancy and related party transactions for the 2025 year, prepared by Grant Thornton and signed by auditors. It references the audit work done for the full financial statements and provides a detailed schedule of related party fund movements, which is beyond a simple announcement and is a form of audit-related disclosure. This aligns with the definition of AR (Audit Report/Information) as a standalone audit‐related report distinct from the full annual report.
2026-04-24 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.